The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome
Primary Purpose
Rett Syndrome
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
calcium
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Rett Syndrome focused on measuring Low bone mass
Eligibility Criteria
Inclusion Criteria
- clinical diagnosis of Rett syndrome
Exclusion Criteria
- parathyroid disease
- renal disease
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Rett Active Supplement
Rett Placebo Supplement
Arm Description
Females with clinical diagnosis of Rett syndrome treated orally daily with calcium carbonate, dose based on Dietary Reference Intake for age, for one year
Females with clinical diagnosis of Rett syndrome treated orally daily with sodium bicarbonate, dose based on equivalent weight for active supplement for age, for one year
Outcomes
Primary Outcome Measures
Bone mineral content (BMC)
Bone mineral content (z-score) measured by dual-energy x-ray absorptiometry
Bone mineral density (BMD)
Bone mineral density (z-score) measured by dual-energy x-ray absorptiometry
Secondary Outcome Measures
Osteocalcin
Serum Osteocalcin (ng/ml)
Bone alkaline phosphatase
Serum Bone alkaline phosphatase (mcg/ml)
C-telopeptide
Serum C-telopeptide (pg/ml)
Calcium/creatinine ratio
Urinary calcium/creatinine ratio (mg/g)
Full Information
NCT ID
NCT05352373
First Posted
April 15, 2022
Last Updated
April 27, 2022
Sponsor
Baylor College of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT05352373
Brief Title
The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome
Official Title
The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
March 1, 2008 (Actual)
Primary Completion Date
March 1, 2012 (Actual)
Study Completion Date
March 1, 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Baylor College of Medicine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Randomized, placebo-controlled trial of oral calcium supplementation for osteopenia in girls and women with Rett syndrome
Detailed Description
Objective: The investigators conducted a randomized, double-blind, placebo-controlled trial to determine the safety and efficacy of oral calcium supplementation for the treatment of bone mineral deficits in individuals with Rett syndrome (RTT).
Methods: The investigators measured total body bone mineral content (BMC) and bone mineral density (BMD) by dual-energy x-ray absorptiometry and biomarkers of bone turnover by clinical laboratory techniques before and one year after oral calcium or placebo supplementation in 32 pre- and post-pubertal girls and young women with RTT. The calcium supplement was calculated to provide a twofold increase in the recommended dietary allowance of calcium for age.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rett Syndrome
Keywords
Low bone mass
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
randomized, double blind
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Rett Active Supplement
Arm Type
Active Comparator
Arm Description
Females with clinical diagnosis of Rett syndrome treated orally daily with calcium carbonate, dose based on Dietary Reference Intake for age, for one year
Arm Title
Rett Placebo Supplement
Arm Type
Placebo Comparator
Arm Description
Females with clinical diagnosis of Rett syndrome treated orally daily with sodium bicarbonate, dose based on equivalent weight for active supplement for age, for one year
Intervention Type
Dietary Supplement
Intervention Name(s)
calcium
Intervention Description
calcium carbonate
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo
Intervention Description
sodium bicarbonate
Primary Outcome Measure Information:
Title
Bone mineral content (BMC)
Description
Bone mineral content (z-score) measured by dual-energy x-ray absorptiometry
Time Frame
change from baseline to 1 year thereafter
Title
Bone mineral density (BMD)
Description
Bone mineral density (z-score) measured by dual-energy x-ray absorptiometry
Time Frame
change from baseline to 1 year thereafter
Secondary Outcome Measure Information:
Title
Osteocalcin
Description
Serum Osteocalcin (ng/ml)
Time Frame
change from baseline to 1 year thereafter
Title
Bone alkaline phosphatase
Description
Serum Bone alkaline phosphatase (mcg/ml)
Time Frame
change from baseline to 1 year thereafter
Title
C-telopeptide
Description
Serum C-telopeptide (pg/ml)
Time Frame
change from baseline to 1 year thereafter
Title
Calcium/creatinine ratio
Description
Urinary calcium/creatinine ratio (mg/g)
Time Frame
change from baseline to 1 year thereafter
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
clinical diagnosis of Rett syndrome
Exclusion Criteria
parathyroid disease
renal disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathleen J Motil, MD, PHD
Organizational Affiliation
Baylor College of Medicine
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
The Role of Dietary Calcium for the Treatment of Osteopenia in Girls With Rett Syndrome
We'll reach out to this number within 24 hrs